Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent

Clinical Infectious Diseases

Volumn 61, Issue 10, 2015, Pages 1558-1565

  Miceli, Marisa H ^a   Kauffman, Carol A ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

Author keywords

aspergillosis; isavuconazole; isavuconazonium sulfate; mucormycosis; triazoles

Indexed keywords

AMFEBUTAMONE; AMPHOTERICIN; ATORVASTATIN; BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; COLCHICINE; CYCLOSPORIN; DABIGATRAN; DIGOXIN; ISAVUCONAZOLE; LOPINAVIR PLUS RITONAVIR; MIDAZOLAM; MYCOPHENOLATE MOFETIL; POSACONAZOLE; RAPAMYCIN; RIFAMPICIN; TACROLIMUS; VORICONAZOLE; ANTIFUNGAL AGENT; NITRILE; PYRIDINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ANTIFUNGAL ACTIVITY; ARTICLE; CHILL; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; DYSPNEA; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERICUM PERFORATUM; HYPERTRANSAMINASEMIA; HYPOKALEMIA; HYPOTENSION; INFUSION RELATED REACTION; INVASIVE ASPERGILLOSIS; MOULD; MUCORMYCOSIS; MULTICENTER STUDY (TOPIC); NAUSEA; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QTC INTERVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RESPIRATORY DISTRESS; SIDE EFFECT; VOMITING; YEAST; ADVERSE DRUG REACTION; INVASIVE PULMONARY ASPERGILLOSIS; TREATMENT OUTCOME;

ANTIFUNGAL AGENTS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; INVASIVE PULMONARY ASPERGILLOSIS; MUCORMYCOSIS; NITRILES; PYRIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; TRIAZOLES;

EID: 84946868768     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ571     Document Type: Article

References (41)

1. Livermore J, Hope W. Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections. Expert Opin Drug Metab Toxicol 2012; 8:759-65.
2. Thompson GR 3rd, Wiederhold NP. Isavuconazole: a comprehensive review of spectrum of activity of a new triazole. Mycopathologia 2010; 170:291-313.
3. Pfaller MA, Messer SA, Rhomberg PR, Jones RN, Castanheira M. In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds. J Clin Microbiol 2013; 51:2608-16.
4. Castanheira M, Messer SA, Rhomberg PR, Dietrich RR, Jones RN, Pfaller MA. Isavuconazole and nine comparator antifungal susceptibility profiles for common and uncommon Candida species collected in 2012: application of new CLSI clinical breakpoints and epidemiological cutoff values. Mycopathologia 2014; 178:1-9.
5. Espinel-Ingroff A, Chowdhary A, Gonzalez GM, et al. Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for the Cryptococcus neoformans-Cryptococcus gattii species complex using the CLSI M27-A3 broth microdilution method. Antimicrob Agents Chemother 2015; 59:666-8.
6. Thompson GR 3rd,Wiederhold NP, Sutton DA, Fothergill A, Patterson TF. In vitro activity of isavuconazole against Trichosporon, Rhodotorula, Geotrichum, Saccharomyces and Pichia species. J Antimicrob Chemother 2009; 64:79-83.
7. Thompson GR 3rd,Wiederhold NP, Fothergill AW, Vallor AC,Wickes BL, Patterson TF. Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans. Antimicrob Agents Chemother 2009; 53:309-11.
8. Guinea J, Recio S, Escribano P, Pelaez T, Gama B, Bouza E. In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens. Antimicrob Agents Chemother 2010; 54:4012-5.
9. Warn PA, Sharp A, Denning DW. In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp. J Antimicrob Chemother 2006; 57: 135-8.
10. Perkhofer S, Lechner V, Lass-Florl C; European Committee on Antimicrobial Susceptibility Testing. In vitro activity of isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob Agents Chemother 2009; 53:1645-7.
11. Guinea J, Pelaez T, Recio S, Torres-Narbona M, Bouza E. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycetes, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrob Agents Chemother 2008; 52:1396-400.
12. Espinel-Ingroff A, Chowdhary A, Gonzalez GM, et al. Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for Aspergillus spp. for the CLSI M38-A2 broth microdilution method. Antimicrob Agents Chemother 2013; 57:3823-8.
13. Gonzalez GM. In vitro activities of isavuconazole against opportunistic filamentous and dimorphic fungi. Med Mycol 2009; 47:71-6.
14. Verweij PE, Gonzalez GM, Wiedrhold NP, et al. In vitro antifungal activity of isavuconazole against 345 Mucorales isolates collected at study centers in eight countries. J Chemother 2009; 21:272-81.
15. Chowdhary A, Kathuria S, Randhawa HS, Gaur SN, Klaassen CH, Meis JF. Isolation of multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR/L98H mutations in the CYP51A gene in India. J Antimicrob Chemother 2012; 67:362-6.
16. van der Linden JW, Snelders E, Kampinga GA, et al. Clinical implications of azole resistance in Aspergillus fumigatus, the Netherlands, 2007-2009. Emerg Infect Dis 2011; 17:1846-54.
17. Badali H, De Hoog GS, Curfs-Breuker I, Andersen B, Meis JF. In vitro activities of eight antifungal drugs against 70 clinical and environmental isolates of Alternaria species. J Antimicrob Chemother 2009; 63: 1295-7.
18. Najafzadeh MJ, Saradeghi Keisari M, Vicente VA, et al. In vitro activities of eight antifungal drugs against 106 waterborne and cutaneous Exophiala species. Antimicrob Agents Chemother 2013; 57:6395-8.
19. Badali H, Mohammadi R, Mashedi O, de Hoog GS, Meis JF. In vitro susceptibility patterns of clinically important Trichophyton and Epidermophyton species against nine antifungal drugs. Mycoses 2015; 58:303-7.
20. Astellas Pharma US. Prescribing information for Cresemba 2015. Available at: www. Astellas. us/docs/cresemba. pdf. Accessed 12 April 2015.
21. US Food and Drug Administration. Isavuconazonium-invasive aspergillosis and invasive mucormycosis. Advisory Committee Briefing Document 2015. Available at: www. FDA. gov/downloads/advisory committees/committeesmeetingmaterials/drugs/anti-infectivedrugs advisorycommittee/ucm430748. pdf. Accessed 12 April 2015.
22. Schmitt-Hoffmann A, Roos B, Heep M, et al. Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother 2006; 50:279-85.
23. Schmitt-Hoffmann A, Roos B, Maares J, et al. Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother 2006; 50:286-93.
24. Cornely OA, Bohme A, Schmitt-Hoffmann A, Ullmann AJ. Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study. Antimicrob Agents Chemother 2015; 59:2078-85.
25. Warn PA, Sharp A, Parmar A, Majithiya J, Denning DW, Hope WW. Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect. Antimicrob Agents Chemother 2009; 53:3453-61.
26. Schmitt-Hoffmann A, Roos B, Spickermann J, et al. Effect of mild and moderate liver disease on the pharmacokinetics of isavuconazole after intravenous and oral administration of a single dose of the prodrug BAL8557. Antimicrob Agents Chemother 2009; 53:4885-90.
27. Yamakazi T, Pearlman H, Kowalski D, Lademacher C, Desai A, Townsend R. Effect of multiple doses of isavuconazole on the pharmacokinetics of CYP3A4 substrate atorvastatin in healthy subjects [abstract A-449]. In: Programand abstracts of the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Denver, CO, 2013.
28. Yamakazi T, DesaiA, PearlmanH, KowalskiD, Lademacher C, Townsend R. No effect on pharmacokinetic and pharmacodynamic parameters of warfarin after coadministration with isavuconazole [abstract A-449]. In: Programand abstracts of the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Denver, CO, 2013.
29. Viljoen J, Azie N, Schmitt-Hoffmann AH, Ghannoum M. A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasis. Antimicrob Agents Chemother 2015; 59:1671-9.
30. Marty FM, Perfect JR, Cornely OA, et al. An open-label phase 3 study of isavuconazole (VITAL): focus on mucormycosis [abstract 824]. In: Program and abstracts of IDWeek, Philadelphia, PA, 2014.
31. Thompson GR 3rd, Rendon A, Santos R, et al. Outcomes in patients with invasive fungal disease caused by dimorphic fungi treated with isavuconazole: experience from the VITAL trial [abstract M-1775]. In: Program and abstracts of the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2014.
32. Kontoyiannis DP, Giladi M, Lee M, et al. A phase 3, randomized, double-blind, non-inferiority trial to evaluate efficacy and safety of isavuconazole versus voriconazole in patients with invasive mold disease (SECURE): outcomes in invasive aspergillosis patients [abstract 1211]. In: Program and abstracts of IDWeek, Philadelphia, PA, 2014.
33. Raad I, Mullane KM, Selleslag D, et al. A phase 3, randomized, doubleblind, non-inferiority trial to evaluate efficacy and safety of isavuconazole vs. voriconazole in patients with invasive mold disease: outcomes in patient with pulmonary infections [abstract 825]. In: Program and abstracts of IDWeek, Philadelphia, PA, 2014.
34. Patterson T, Selleslag D, Mullane KM, et al. A phase 3, randomized, double-blind, non-inferiority trial to evaluate efficacy and safety of isavuconazole versus voriconazole in patients with invasive mold disease (SECURE): outcomes in neutropenic patients [abstract 1210]. In: Program and abstracts of IDWeek, Philadelphia, PA, 2014.
35. De Pauw B,Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46:1813-21.
36. Segal BH, Herbrecht R, Stevens DA, et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis 2008; 47: 674-83.
37. Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41:634-53.
38. Lanternier F, Dannaoui E, Morizot G, et al. A global analysis of mucormycosis in France: The RetroZygo Study (2005-2007). Clin Infect Dis 2012; 54:S35-43.
39. Greenberg RN, Mullane K, van Burik JA, et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006; 50: 126-33.
40. van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006; 42:e61-5.
41. Cornely OA, Ostrosky-Zeichner L, Rahav G, et al. Outcomes in patients with invasive mold disease caused by Fusarium or Scedosporium spp. treated with isavuconazole: experience from the VITAL and SECURE trials [abstract M-1760]. In: Program and abstracts of the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2014.